According to Wedbush analysts, Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) is now expected to announce $2.86 as full year 2020 EPS. This is down from their previous estimate of $2.34 for the current year. This report was issued on the 10th of December and also includes information on the company’s estimated Q4 EPS that stands at $0.72.
KPTI stocks traded at $15.36 this Monday. The company’ current market capitalization stands at $1.13 billion. It has a PE ratio of -5.30, along with a beta of 0.99 at the moment. The 12-monthly high to low ranges from $13.39 to $29.61. The 50SMA (Simple Moving Average) stands at $15.46 and its 200SMA stands at $16.33. The debt-to-equity of this company is 1.38. The current ratio is 5.42 and a quick ratio of 5.39.
Karyopharm Therapeutics, Inc. (KPTI) Stock analysis
The quarterly earnings report for the previous quarter was released on the 2nd of November. The earnings stood at $0.73 EPS that was similar to the general consensus of $0.73. The company’s return on equity stood at -187.66% along with the net margin of 221.23%.
NASDAQ: KPTI has recently been the subject of a lot of reports by research analysts. Some such Zacks Investment Research, SVB Leerink, Morgan Stanley, BidAskClub, and so on among other equities posted reports on this firm over the last few months.
Karyopharm Therapeutics, Inc. was recently rated “hold” by Zacks Investment Research on October 6. Morgan Stanley set the rating of “overweight” on November 3. On the same day, SVB Leerink issued the rating of “outperform” to KPTI stocks.
The average consensus rating of Blackbaud, Inc. currently stands at “Buy” and the consensus on the target price is $31.60. Several hedge funds have also been involved in buying and selling of NASDAQ: KPTI shares recently.